AGEN
Agenus Inc. NASDAQ Listed Feb 8, 2000$3.75
Mkt Cap $144.0M
52w Low $2.71
22.5% of range
52w High $7.34
50d MA $3.72
200d MA $3.98
P/E (TTM)
-1129.4x
EV/EBITDA
-40.3x
P/B
—
Debt/Equity
-1.2x
ROE
13.9%
P/FCF
-0.6x
RSI (14)
—
ATR (14)
—
Beta
1.61
50d MA
$3.72
200d MA
$3.98
Avg Volume
707.0K
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
3 Forbes Road · Lexington, MA 02421-7305 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | AMC | -1.27 | 0.56 | +144.1% | 3.29 | +1.5% | +21.3% | -5.8% | +1.3% | -2.6% | -0.5% | — |
| Nov 10, 2025 | AMC | 2.63 | 1.94 | -26.2% | 4.21 | -0.7% | +1.4% | +3.7% | -2.3% | +0.2% | -0.5% | — |
| Aug 11, 2025 | AMC | -0.78 | -1.00 | -28.2% | 4.27 | +0.0% | +12.6% | -5.6% | +0.2% | +1.8% | -2.2% | — |
| May 12, 2025 | AMC | -1.61 | -1.03 | +36.0% | 3.50 | +1.1% | -3.4% | +2.7% | -2.6% | +3.0% | +8.9% | — |
| Mar 11, 2025 | AMC | -2.36 | -2.04 | +13.6% | 2.05 | +2.4% | -8.8% | -10.2% | +10.7% | -4.3% | -2.8% | — |
| Nov 12, 2024 | AMC | -2.33 | -3.08 | -32.2% | 3.11 | +1.3% | -2.6% | -8.6% | -1.8% | -3.3% | -2.3% | — |
| Aug 8, 2024 | AMC | -1.44 | -2.52 | -75.0% | 5.28 | -2.3% | -3.6% | +0.8% | -8.2% | -2.8% | +12.9% | — |
| May 7, 2024 | AMC | -3.22 | -3.04 | +5.6% | 12.01 | +0.4% | -4.5% | +2.2% | -10.5% | +5.7% | -3.5% | — |
| Mar 14, 2024 | AMC | -0.40 | -2.60 | -550.0% | 11.99 | +0.9% | -9.9% | -1.9% | +6.2% | -1.4% | +1.4% | — |
| Nov 7, 2023 | AMC | -3.80 | -3.20 | +15.8% | 16.40 | +4.9% | +2.4% | -10.3% | -13.7% | -3.4% | +16.4% | — |
| Aug 8, 2023 | AMC | -4.00 | -4.00 | +0.0% | 25.00 | +4.8% | +2.4% | +3.1% | +2.3% | -0.7% | +0.7% | — |
| May 9, 2023 | AMC | -4.20 | -4.40 | -4.8% | 30.00 | +1.3% | +2.7% | -9.1% | +1.4% | +7.0% | -7.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.07 | $5.08 | +0.2% | -4.7% | -1.9% | -5.5% | -0.7% | +0.4% |
| Aug 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.54 | $4.52 | -0.4% | -6.4% | -1.6% | -0.5% | +2.4% | +0.7% |
| Jun 4 | Baird | Maintains | Neutral → Neutral | — | $5.00 | $5.36 | +7.2% | +12.6% | -8.3% | +15.3% | -6.7% | -3.2% |
| Jun 4 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $5.00 | $5.36 | +7.2% | +12.6% | -8.3% | +15.3% | -6.7% | -3.2% |
| May 13 | Baird | Maintains | Neutral → Neutral | — | $3.50 | $3.54 | +1.1% | -3.4% | +2.7% | -2.6% | +3.0% | +8.9% |
| May 13 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.50 | $3.54 | +1.1% | -3.4% | +2.7% | -2.6% | +3.0% | +8.9% |
| Apr 30 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.05 | $3.06 | +0.3% | -5.2% | -1.0% | +8.7% | -0.6% | -3.9% |
| Mar 18 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.78 | $1.73 | -2.8% | -2.8% | +0.0% | -3.5% | -3.6% | +1.9% |
| Mar 12 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $2.05 | $2.10 | +2.4% | -8.8% | -10.2% | +10.7% | -4.3% | -2.8% |
| Mar 12 | Baird | Maintains | Neutral → Neutral | — | $2.05 | $2.10 | +2.4% | -8.8% | -10.2% | +10.7% | -4.3% | -2.8% |
| Jan 22 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.83 | $3.84 | +0.3% | -4.4% | +2.7% | -5.1% | +0.8% | -1.1% |
| Dec 5 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.43 | $3.42 | -0.3% | -8.5% | +14.0% | -2.2% | -4.0% | -2.7% |
| Nov 29 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.49 | $3.52 | +0.9% | -2.0% | +9.1% | -6.2% | -2.0% | -8.5% |
| Nov 12 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.90 | $3.60 | -7.7% | -20.3% | -2.6% | -8.6% | -1.8% | -3.3% |
| Aug 14 | B. Riley Securities | Maintains | Buy → Buy | — | $4.71 | $4.71 | +0.0% | -2.8% | +12.9% | +2.1% | -3.6% | -2.8% |
| Jul 19 | Jefferies | Downgrade | Buy → Hold | — | $7.30 | $7.00 | -4.1% | -17.9% | +14.4% | +0.9% | -11.3% | -2.6% |
| Jul 18 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $17.73 | $6.96 | -60.7% | -58.8% | -17.9% | +14.4% | +0.9% | -11.3% |
| Jun 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.12 | $14.16 | +0.3% | +18.6% | -0.4% | -14.4% | +1.8% | +4.1% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.35 | $12.55 | +1.6% | +10.3% | +12.0% | -1.4% | +0.5% | +3.8% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.95 | $12.45 | -3.9% | -7.3% | -4.5% | +2.2% | -10.5% | +5.7% |
| Mar 18 | B. Riley Securities | Maintains | Buy → Buy | — | $10.80 | $11.40 | +5.6% | -1.9% | +6.2% | -1.4% | +1.4% | -2.8% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.17 | $13.40 | +1.7% | -9.0% | -9.9% | -1.9% | +6.2% | -1.4% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.20 | $27.40 | +0.7% | -8.1% | +2.4% | +3.1% | +2.3% | -0.7% |
| Jul 3 | EF Hutton | Maintains | Buy → Buy | — | $32.00 | $32.40 | +1.2% | -5.0% | +10.5% | -6.5% | +4.5% | +11.0% |
| Jul 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.00 | $32.40 | +1.2% | -5.0% | +10.5% | -6.5% | +4.5% | +11.0% |
| Jun 6 | Baird | Maintains | Outperform → Outperform | — | $34.60 | $35.20 | +1.7% | +6.9% | +1.6% | +8.5% | -2.5% | +0.5% |
| Jun 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.00 | $32.20 | +0.6% | +8.1% | +6.9% | +1.6% | +8.5% | -2.5% |
| Jun 5 | EF Hutton | Maintains | Buy → Buy | — | $32.00 | $32.20 | +0.6% | +8.1% | +6.9% | +1.6% | +8.5% | -2.5% |
| May 26 | EF Hutton | Maintains | Buy → Buy | — | $28.20 | $29.00 | +2.8% | +2.8% | +0.7% | +6.8% | +1.9% | +0.6% |
| Mar 29 | B. Riley Securities | Maintains | Buy → Buy | — | $29.60 | $29.80 | +0.7% | +5.4% | -7.1% | +4.8% | +3.3% | -5.1% |
| Mar 28 | EF Hutton | Maintains | Buy → Buy | — | $31.20 | $32.00 | +2.6% | -5.1% | +5.4% | -7.1% | +4.8% | +3.3% |
| Mar 15 | EF Hutton | Maintains | Buy → Buy | — | $35.80 | $35.40 | -1.1% | +5.6% | -3.2% | -7.1% | -3.5% | -0.6% |
| Dec 22 | EF Hutton | Maintains | Buy → Buy | — | $48.80 | $48.40 | -0.8% | +4.9% | -4.3% | -5.3% | -6.5% | +6.5% |
| Dec 8 | EF Hutton | Maintains | Buy → Buy | — | $49.40 | $51.60 | +4.5% | +1.6% | -3.6% | +13.6% | +1.5% | -3.6% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $51.80 | $51.80 | +0.0% | +18.5% | -3.6% | -1.7% | +0.3% | +0.7% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $66.20 | $69.00 | +4.2% | +0.3% | +7.2% | -0.8% | -0.3% | -0.3% |
| Apr 22 | B. Riley FBR | Maintains | Buy → Buy | — | $50.60 | $51.40 | +1.6% | +0.4% | +2.4% | +1.2% | -1.1% | +2.3% |
| Oct 28 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $86.60 | $83.00 | -4.2% | -5.5% | -2.9% | -2.5% | -1.6% | -2.1% |
| Oct 28 | H.C. Wainwright | Downgrade | Buy → Neutral | — | $86.60 | $83.00 | -4.2% | -5.5% | -2.9% | -2.5% | -1.6% | -2.1% |
| Jul 29 | Jefferies | Maintains | Buy → Buy | — | $107.60 | $108.40 | +0.7% | +3.2% | +1.8% | -1.8% | +3.6% | -1.7% |
| Mar 11 | Maxim Group | Upgrade | Hold → Buy | — | $74.00 | $75.40 | +1.9% | +8.1% | +0.8% | -8.7% | -0.8% | +2.5% |
| Mar 9 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $81.40 | $81.20 | -0.2% | -5.4% | -3.9% | +8.1% | +0.8% | -8.7% |
| Oct 27 | Maxim Group | Downgrade | Buy → Hold | — | $99.80 | $106.00 | +6.2% | -4.8% | -0.6% | -1.9% | -1.5% | +4.4% |
| Jun 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $176.80 | $176.40 | -0.2% | +0.9% | +5.2% | +1.1% | +2.0% | +0.1% |
| Apr 3 | McNicoll Lewis Vlak | Maintains | Buy → Buy | — | $64.20 | $64.80 | +0.9% | -4.7% | -8.5% | +0.7% | -2.5% | +6.9% |
| Feb 24 | H.C. Wainwright | Maintains | Buy → Buy | — | $77.60 | $83.00 | +7.0% | +8.5% | +6.7% | +13.6% | -4.1% | +0.0% |
| Jun 18 | Maxim Group | Maintains | Buy → Buy | — | $75.00 | $75.40 | +0.5% | +0.8% | +5.3% | -6.8% | +2.7% | -5.2% |
| Apr 2 | JMP Securities | Maintains | Market Outperform → Outperform | — | $76.80 | $79.20 | +3.1% | +3.4% | -3.5% | +2.1% | -2.0% | +7.3% |
No insider trades available.
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Agen Biotech's 8-K filing suggests a material corporate announcement, likely triggering significant price movement; investors should monitor for earnings surprises, strategic partnerships, or regulatory developments affecting the biotech stock's trajectory.
Mar 26
8-K
Unknown — 8-K Filing
Agenus has secured manufacturing capacity for its lead BOT+BAL combination therapy, indicating progression toward commercialization and reducing execution risk for this potentially revenue-generating asset.
Mar 16
Data updated apr 24, 2026 4:31pm
· Source: massive.com